Company intelligence / Profile preview
Neurotune AG
Schlieren, ZH, Switzerlandneurotune.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Preclinical
01
Overview
Neurotune AG develops novel small-molecule and protein-based drugs targeting neuromuscular disorders and neuropathic pain. Its lead compound has advanced to Phase II clinical trials for neuropathic pain in HIV patients. The company also explores treatments for sarcopenia, SMA, ALS, and kidney diagnostics.
- Therapeutic areas
- NeurologyNephrology
- Modalities
- Small moleculesProtein drug candidates (preclinical work)Diagnostic assays (ELISA, preclinical work)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Neurotune AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neurotune AG.